Clinical Trials
29 trialsWindow of Opportunity Study Targeting the Inflammatory Milieu
University of Colorado, Denver
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Université de Sherbrooke
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
AstraZeneca
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
Case Comprehensive Cancer Center
REACT
Imperial College London
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
University of Wisconsin, Madison
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer
Maastricht University Medical Center
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Hartford Hospital
Changes in Biomarkers Using Prostaglandin Inhibitors
Hartford Hospital
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
University of Kansas Medical Center
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Alliance for Clinical Trials in Oncology
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
National Cancer Institute (NCI)
Protocol for Women at Increased Risk of Developing Breast Cancer
University of Kansas Medical Center
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
M.D. Anderson Cancer Center
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer
Organisation for Oncology and Translational Research
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
Pfizer
A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy
University of Kansas Medical Center